🚀 VC round data is live in beta, check it out!
Aura Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aura Biosciences and similar public comparables like Duopharma Biotech, Avacta Group, Recbio, Neurogene and more.
Aura Biosciences Overview
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Founded
2009
HQ
Employees
109
Website
Sectors
Financials (LTM)
EV
$218M
Aura Biosciences Financials
Aura Biosciences reported last 12-month revenue of —.
In the same LTM period, Aura Biosciences generated had net loss of ($113M).
Revenue (LTM)
Aura Biosciences P&L
In the most recent fiscal year, Aura Biosciences reported revenue of — and EBITDA of ($95M).
Aura Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($95M) | XXX | XXX | XXX |
| Net Profit | ($113M) | XXX | ($87M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aura Biosciences Stock Performance
Aura Biosciences has current market cap of $362M, and enterprise value of $218M.
Market Cap Evolution
Aura Biosciences' stock price is $5.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $218M | $362M | 0.0% | XXX | XXX | XXX | $-1.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAura Biosciences Valuation Multiples
Aura Biosciences trades at (2.3x) EV/EBITDA.
Aura Biosciences Financial Valuation Multiples
As of March 21, 2026, Aura Biosciences has market cap of $362M and EV of $218M.
Equity research analysts estimate Aura Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aura Biosciences has a P/E ratio of (3.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $362M | XXX | $362M | XXX | XXX | XXX |
| EV (current) | $218M | XXX | $218M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (2.3x) | XXX | XXX | XXX |
| P/E | (3.2x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aura Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aura Biosciences Margins & Growth Rates
Aura Biosciences' revenue in the last fiscal year grew by —.
Aura Biosciences' revenue per employee in the last FY averaged $0.0M.
Aura Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 13% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aura Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Duopharma Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Medigen Vaccine Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aura Biosciences M&A Activity
Aura Biosciences acquired XXX companies to date.
Last acquisition by Aura Biosciences was on XXXXXXXX, XXXXX. Aura Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aura Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAura Biosciences Investment Activity
Aura Biosciences invested in XXX companies to date.
Aura Biosciences made its latest investment on XXXXXXXX, XXXXX. Aura Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aura Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aura Biosciences
| When was Aura Biosciences founded? | Aura Biosciences was founded in 2009. |
| Where is Aura Biosciences headquartered? | Aura Biosciences is headquartered in United States. |
| How many employees does Aura Biosciences have? | As of today, Aura Biosciences has over 109 employees. |
| Who is the CEO of Aura Biosciences? | Aura Biosciences' CEO is Elisabet de los Pinos. |
| Is Aura Biosciences publicly listed? | Yes, Aura Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Aura Biosciences? | Aura Biosciences trades under AURA ticker. |
| When did Aura Biosciences go public? | Aura Biosciences went public in 2021. |
| Who are competitors of Aura Biosciences? | Aura Biosciences main competitors are Duopharma Biotech, Avacta Group, Recbio, Neurogene. |
| What is the current market cap of Aura Biosciences? | Aura Biosciences' current market cap is $362M. |
| Is Aura Biosciences profitable? | No, Aura Biosciences is not profitable. |
| What is the current net income of Aura Biosciences? | Aura Biosciences' last 12 months net income is ($113M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.